COPYRIGHT© Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

COPYRIGHT© 2018  吉林紫鑫药业股份有限公司

Announcement of Jilin Zixin Pharmaceutical Co., Ltd. on the commitment and performance of the actual controllers, shareholders,

Page view

Stock code: 002118 Securities abbreviation: Zixin Pharmaceutical Announcement No.: 2014-007

Jilin Zixin Pharmaceutical Co., Ltd.

Announcement on the commitments and performance of the actual controllers, shareholders, related parties, purchasers and listed companies of listed companies

The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.

Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as “Company”) is under the “Guidelines for the Supervision of Listed Companies No. 4 – Actual Controllers, Shareholders, Related Parties, Acquirers and Listed Companies Committed and Performed by the China Securities Regulatory Commission” (hereinafter referred to as “Company”) The following is referred to as: the regulatory guidelines) and the China Securities Regulatory Commission, Jilin Securities Regulatory Bureau, "Notice on Doing a Good Job of the Actual Controllers, Shareholders, Related Parties, Purchasers and Listed Companies of Listed Companies and Performing Special Disclosures" (Ji Zheng Jian Fa [2014] No. 23) The relevant requirements of the company's actual controllers, shareholders, related parties, purchasers and other related entities were verified. The commitments that have not been fulfilled are announced as follows:

First, avoid the commitment of horizontal competition

The company and the controlling shareholder Dunhua Kangping Investment Co., Ltd. (hereinafter referred to as Kangping Company), the company's actual controller Mr. Guo Chunsheng and their shareholding relatives respectively signed the "Commitment Letter on Avoiding Horizontal Competition", pledge not to present or future Businesses or activities that compete or may compete with the company's business in any way, including but not limited to sole business, joint ventures, joint ventures, and possession of shares or interests in other companies or businesses.

Commitment period: long-term effective

Commitment to fulfillment: As of the date of the announcement, the promisee strictly fulfilled the above commitments.

2. The company's directors, supervisors and senior management personnel promise that the shares transferred by the company during the company's tenure shall not exceed 25% of the total number of shares held by the company; the company's shares held by the company will not be transferred within six months after leaving the company; The proportion of shares sold in the company within 12 months after six months shall not exceed 50% of the total number of shares held by the company.

Commitment period: long-term effective

Commitment to fulfillment: As of the date of the announcement, the promisee strictly fulfilled the above commitments.

In addition to the above commitments, as of the date of this announcement, the relevant parties are not obliged to comply with the requirements of the “Regulations” and the unfulfilled commitments.

 

 

Special announcement.

Jilin Zixin Pharmaceutical Co., Ltd. Board of Directors

February 13, 2014